ASCO Annual Meeting | Conference

Isatuximab Triplet Significantly Improves PFS in Myeloma

June 3rd 2019

Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial

June 3rd 2019

A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.

High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy

June 2nd 2019

Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.

Lurbinectedin Shows Promise as Single-Agent in Second-Line SCLC

June 2nd 2019

Lurbinectedin monotherapy achieved an overall response rate of 35.2% as a second-line treatment for patients with small cell lung cancer, according to findings from a phase II basket trial presented at the 2019 ASCO Annual Meeting.

Maintenance Olaparib Improves PFS in BRCA+ Metastatic Pancreatic Cancer

June 2nd 2019

Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Enzalutamide Increases Survival in mHSPC Over Other Anti-Androgens

June 2nd 2019

Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.

Alarm Sounded Over Multiple Myeloma Outcomes Versus Socioeconomics

June 2nd 2019

Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.

Medicaid Expansion Helps Reduce Racial Disparities in Access to Cancer Care

June 2nd 2019

The expansion of Medicaid nearly eliminated racial disparities in time to cancer treatment.

ACA Improved Ovarian Cancer Diagnosis and Time to Treatment

June 2nd 2019

Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.

Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer

June 2nd 2019

Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

June 2nd 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Open Source System Debuts for EHR Data Sharing

June 2nd 2019

A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment.

New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer

June 1st 2019

The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.

Apalutamide Extends Survival in Metastatic Castration-Sensitive Prostate Cancer

June 1st 2019

Adding apalutamide to androgen deprivation therapy (ADT) reduced the risk of the death by 33% in patients with metastatic castration-sensitive prostate cancer compared with ADT alone.

Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer

June 1st 2019

Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.

Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer

June 1st 2019

Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

June 1st 2019

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Agarwal on the TALAPRO-2 Trial in mCRPC

June 1st 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

ASCO 2019: Oncology Leaders Select Top Studies

May 29th 2019

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.